Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.
NSCLC
PIOS
Patras Immunotherapy Score
biomarker
nivolumab
pembrolizumab
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
09
2021
accepted:
10
08
2022
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
16
9
2022
Statut:
epublish
Résumé
Recently, the Patras Immunotherapy Score (PIOS) has been developed to estimate the survival benefit of patients with advanced non-small-cell lung cancer (aNSCLC) treated with nivolumab or pembrolizumab. The aim of this study was to validate the clinical value of PIOS in an external cohort of aNSCLC patients. PIOS is a baseline formula produced by the combination of performance status, body mass index, age and line of treatment. In this multicentre study, 626 patients with confirmed NSCLC pathology, who had been treated with nivolumab or pembrolizumab, as well as 444 patients with aNSCLC, who had been managed with chemotherapy alone, were retrospectively enrolled. Predictive and prognostic values of PIOS were finally evaluated. Patients treated with immunotherapy and higher PIOS score had an improved progression-free survival not only in univariate [hazard ratio (HR) = 0.621, This study provides further validation of PIOS in aNSCLC patients treated with anti-PD-1 monotherapy.
Sections du résumé
Background
UNASSIGNED
Recently, the Patras Immunotherapy Score (PIOS) has been developed to estimate the survival benefit of patients with advanced non-small-cell lung cancer (aNSCLC) treated with nivolumab or pembrolizumab. The aim of this study was to validate the clinical value of PIOS in an external cohort of aNSCLC patients.
Methods
UNASSIGNED
PIOS is a baseline formula produced by the combination of performance status, body mass index, age and line of treatment. In this multicentre study, 626 patients with confirmed NSCLC pathology, who had been treated with nivolumab or pembrolizumab, as well as 444 patients with aNSCLC, who had been managed with chemotherapy alone, were retrospectively enrolled. Predictive and prognostic values of PIOS were finally evaluated.
Results
UNASSIGNED
Patients treated with immunotherapy and higher PIOS score had an improved progression-free survival not only in univariate [hazard ratio (HR) = 0.621,
Conclusions
UNASSIGNED
This study provides further validation of PIOS in aNSCLC patients treated with anti-PD-1 monotherapy.
Identifiants
pubmed: 36105886
doi: 10.1177/17588359221122728
pii: 10.1177_17588359221122728
pmc: PMC9465562
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359221122728Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Competing interests: The authors declare that there is no conflict of interest.
Références
Ann Oncol. 2019 Aug 1;30(8):1244-1253
pubmed: 31143921
Cancer Immunol Immunother. 2018 Sep;67(9):1349-1353
pubmed: 29947960
Cancers (Basel). 2019 Feb 10;11(2):
pubmed: 30744168
World J Clin Oncol. 2018 Nov 10;9(7):140-147
pubmed: 30425939
Front Med (Lausanne). 2020 Mar 24;7:90
pubmed: 32266275
J Thorac Oncol. 2019 Sep;14(9):1608-1618
pubmed: 31195179
Nat Rev Clin Oncol. 2020 Feb;17(2):73-74
pubmed: 31907372
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Oncologist. 2017 Aug;22(8):963-971
pubmed: 28476944
Cancers (Basel). 2019 Dec 05;11(12):
pubmed: 31817541
Semin Oncol. 2018 Aug;45(4):220-225
pubmed: 30391014
Cancers (Basel). 2020 May 16;12(5):
pubmed: 32429368
Oncoimmunology. 2018 Aug 20;7(11):e1507262
pubmed: 30377569
J Clin Lab Anal. 2019 Oct;33(8):e22964
pubmed: 31282096
Clin Chem. 2019 Oct;65(10):1228-1238
pubmed: 31315901
Cancer Med. 2018 Jan;7(1):13-20
pubmed: 29150906
Eur J Cancer. 2016 Jul;62:138-45
pubmed: 27237360
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Clin Lung Cancer. 2020 Jul;21(4):e286-e293
pubmed: 32089478
Front Cell Dev Biol. 2020 Jul 21;8:672
pubmed: 32793604
JAMA Oncol. 2018 Mar 01;4(3):351-357
pubmed: 29327044
J Immunother Cancer. 2019 Feb 27;7(1):57
pubmed: 30813970
Clin Cancer Res. 2018 Nov 1;24(21):5347-5356
pubmed: 29898988
Front Oncol. 2020 Nov 30;10:568174
pubmed: 33330041
Br J Cancer. 2020 Feb;122(3):340-347
pubmed: 31761899
J Transl Med. 2019 Mar 27;17(1):99
pubmed: 30917841
Lung Cancer. 2020 Jul;145:95-104
pubmed: 32417680
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Immunotherapy. 2019 Aug;11(12):993-1003
pubmed: 31319742